2021
Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan
Dillon EM, Wei SD, Gupta DK, Nian H, Rodibaugh BS, Bachmann KN, Naftilan AJ, Stevenson LW, Brown NJ. Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan. Journal Of Cardiac Failure 2021, 27: 1231-1239. PMID: 34133968, PMCID: PMC8578199, DOI: 10.1016/j.cardfail.2021.05.026.Peer-Reviewed Original ResearchMeSH KeywordsAminobutyratesBiphenyl CompoundsHeart FailureHumansMass SpectrometryNatriuretic Peptide, BrainValsartanConceptsSacubitril/valsartanSacubitril/valsartan treatmentHeart failureBNP1-32NT-proBNPValsartan treatmentActive B-type natriuretic peptideEnd-stage renal diseaseB-type natriuretic peptideNT-proBNP immunoassaysPg/mLRenal diseaseNatriuretic peptideBNP productionHealthy volunteersBNPPg/ValsartanPatientsInhibition of degradationPeptide immunoassayBNP degradationTreatmentImmunoassayMS accounts
2016
B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS
Semler MW, Marney AM, Rice TW, Nian H, Yu C, Wheeler AP, Brown NJ, Network N. B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS. CHEST Journal 2016, 150: 102-111. PMID: 27018313, PMCID: PMC4980545, DOI: 10.1016/j.chest.2016.03.017.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideAcute respiratory distress syndromeConservative fluid managementRespiratory distress syndromeLiberal fluid managementVentilator-free daysNatriuretic peptideFluid managementDistress syndromeAldosterone concentrationOverall mortalityB-type natriuretic peptide concentrationsCatheter Treatment TrialNatriuretic peptide concentrationsLow aldosterone concentrationsHospital mortalityMedian aldosteroneMultivariable analysisStudy enrollmentTreatment trialsPlasma concentrationsRetrospective analysisFluid balanceAldosteroneFluid strategy
2014
Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm
Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ. Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm. Journal Of The American Heart Association 2014, 3: e001075. PMID: 25158865, PMCID: PMC4310400, DOI: 10.1161/jaha.114.001075.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Brain natriuretic peptideForearm blood flowNatriuretic peptideDPP4 inhibitionBlood flowPeptide-1Placebo-controlled crossover studyDipeptidyl peptidase-4 inhibitorsDipeptidyl peptidase-4 inhibitionForearm vascular resistanceDose-dependent vasodilationMean arterial pressureGLP-1 concentrationsHuman forearmSitagliptin useDirect vasodilatorVascular resistanceVasodilator responseVascular effectsArterial pressureBrachial arteryDiabetes mellitusGlycemic controlNorepinephrine releaseChanges in B-Type Natriuretic Peptide and BMI Following Roux-en-Y Gastric Bypass Surgery
Marney AM, Brown NJ, Tamboli R, Abumrad N. Changes in B-Type Natriuretic Peptide and BMI Following Roux-en-Y Gastric Bypass Surgery. Diabetes Care 2014, 37: e70-e71. PMID: 24652734, PMCID: PMC3964493, DOI: 10.2337/dc13-2449.Peer-Reviewed Original ResearchAnastomosis, Roux-en-YBody Mass IndexFemaleGastric BypassHumansMaleNatriuretic Peptide, BrainObesity, Morbid